Observational studyEuropean journal of neurology2022

Real-life experience with inotersen in hereditary transthyretin amyloidosis with late-onset phenotype: Data from an early-access program in Italy.

Marco Luigetti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.